glp-1 novo Nordisk plans to slash prices Blockbuster GLP-1 Diabetes and Weight
Description
Pillar 7: Metformin (mostly hepatic) Metformin is often described as a general insulin sensitiser, but mechanistically, its clinically relevant effects are largely hepatic (liver)
However, we need to acknowledge limitations like low bioavailability and trial heterogeneity, which could affect how well the findings apply more broadly
The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center, based at the University of Copenhagen, Denmark, and is partially funded by an unconditional donation from the Novo Nordisk Foundation (www.cbmr.ku.dk) (grant numbers NNF18CC0034900 and NNF23SA0084103)
Approval for treatment is not guaranteed - your Provider makes that determination based on your health profile
Do not shake vigorously gentle swirling is preferred
